BioMérieux
T2 Biosystems Pathogen Detection Patent Upheld in Europe
French diagnostics maker BioMérieux and other undisclosed firms had filed an opposition to the patent in May 2023.
BioMérieux Q2 Revenues Rise 8 Percent
The firm raised its full-year 2024 guidance to sales growth at constant exchange rates of 8 percent to 10 percent, up from previous guidance of 6 percent to 8 percent growth.
At the ADLM annual meeting, firms said they see game-changing opportunities for platforms that provide the right combination of clinical utility and convenience.
FDA Grants 510(k) Clearances to BioMérieux, Roche, Philips, Diasorin, Others in June
Antimicrobial susceptibility tests, digital pathology slide creation and analysis systems, and a molecular fungemia panel were among the products cleared in June.
BioMérieux Respiratory/Sore Throat Mini Panel Gets FDA Special 510(k) Clearance, CLIA Waiver
The firm said that it expects its SpotFire Respiratory/Sore Throat (R/ST) Panel Mini test to be available in the US in the third quarter of 2024.